Cargando…

Ten years’ clinical experience with biosimilar human growth hormone: a review of efficacy data

In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer). Data continue to be collected on the long-term efficacy of biosimila...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Siguero, Juan Pedro, Pfäffle, Roland, Chanson, Philippe, Szalecki, Mieczyslaw, Höbel, Nadja, Zabransky, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439972/ https://www.ncbi.nlm.nih.gov/pubmed/28553079 http://dx.doi.org/10.2147/DDDT.S130320

Ejemplares similares

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
por: Borrás Pérez, Maria Victoria, et al.
Publicado: (2017)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
por: Schiestl, Martin, et al.
Publicado: (2017)

Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
por: Romer, Tomasz, et al.
Publicado: (2011)

Ten years of biosimilar recombinant human growth hormone in Europe
por: Saenger, Paul
Publicado: (2017)

Development and 10-year history of a biosimilar: the example of Binocrit(®)
por: Aapro, Matti, et al.
Publicado: (2018)

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017)

Efficacy and Safety of Biosimilar Growth Hormone in Indian Children
por: Khadilkar, Vaman, et al.
Publicado: (2018)

Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020)

Current Status of Biosimilar Growth Hormone
por: Saenger, Paul
Publicado: (2009)

No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope(®)) During a Phase III Clinical Trial
por: Borrás Pérez, Victoria, et al.
Publicado: (2015)

Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
por: Schwarz, Hans-Peter, et al.
Publicado: (2016)

Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019)

Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
por: Lecka-Ambroziak, Agnieszka, et al.
Publicado: (2020)

Isolated Growth Hormone Deficiency and Idiopathic Short Stature: Comparative Efficiency after Growth Hormone Treatment up to Adult Height
por: Ariza-Jimenez, Ana-Belen, et al.
Publicado: (2021)

One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
por: Schwarz, Hans-Peter, et al.
Publicado: (2014)

Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age
por: Juul, Anders, et al.
Publicado: (2022)

Growth hormone improves short stature in children with Shwachman-Diamond syndrome
por: Bogusz-Wójcik, Agnieszka, et al.
Publicado: (2021)

Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes, Responsible for the Occurrence of Obesity
por: Barczynska, Renata, et al.
Publicado: (2016)

Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
por: Krendyukov, A., et al.
Publicado: (2017)

Assessment of insulin resistance in preterm children appropriate for gestational age versus term and preterm children with intrauterine growth restriction
por: Korpysz, Alicja, et al.
Publicado: (2021)

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020)

Factors influencing height gain in children born small for gestational age treated with recombinant growth hormone: what extent is puberty involved?
por: Arroyo Ruiz, Ramón, et al.
Publicado: (2022)

Evolving pituitary hormone deficits in primarily isolated GHD: a review and experts’ consensus
por: Binder, Gerhard, et al.
Publicado: (2020)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults)
por: Höybye, Charlotte, et al.
Publicado: (2021)

SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)
por: Schwarz, Hans-Peter, et al.
Publicado: (2019)

SUN-255 PATRO Children, a Multi-Center, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment: Comparing United States (US) and Rest of World (ROW) Data
por: Backeljauw, Philippe, et al.
Publicado: (2019)

Genetics of Growth Disorders—Which Patients Require Genetic Testing?
por: Argente, Jesús, et al.
Publicado: (2019)

SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
por: Iughetti, Lorenzo, et al.
Publicado: (2016)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

Coexistence of resistance to thyroid hormone and ectopic thyroid: ten-year follow-up
por: Guo, Man-Li, et al.
Publicado: (2016)

Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency
por: Hyldstrup, L., et al.
Publicado: (2011)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Pituitary stalk thickening in patients under 18 years of age - the most common causes and diagnostic procedures
por: Moszczyńska, Elżbieta, et al.
Publicado: (2022)

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
por: Flodmark, Carl-Erik, et al.
Publicado: (2013)

Genotypic Findings in Noonan and Non-Noonan RASopathies and Patient Eligibility for Growth Hormone Treatment
por: Carcavilla, Atilano, et al.
Publicado: (2023)

Ten Years on
por: Dunn, Rebecca B., et al.
Publicado: (1987)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_81aqimjnlmt616aqrkp61p5sh1